Langes oral solution 50 mg/ml. 200 ml.

Description

LANGES 200ml STORAGE
active substance: carbocysteine

1 ml of the drug contains carbocysteine ​​50 mg

Excipients: sodium saccharin, methyl parahydroxybenzoate (E 218), raspberry flavor, sodium hydroxide, carmellose sodium, purified water.

LANGES 200ml PHARMACEUTICAL FORM
The solution is oral.

LANGES 200ml MAIN PHYSICO-CHEMICAL PROPERTIES
a clear solution of light yellow color with a characteristic smell of raspberries.

LANGES 200ml PHARMACOTHERAPEUTIC GROUP
Mucolytics. Carbocysteine. ATX code R05C B03.

PHARMACOLOGICAL PROPERTIES

Pharmacodynamics

Carbocysteine ​​affects the gel phase of the mucus of the respiratory tract: by rupturing the disulfide bridges of glycoproteins causes a liquefaction of excessively viscous bronchial secretion, which promotes the excretion of sputum.

The mucoregulatory effect of carbocysteine ​​is associated with the activation of sialic transferase & ndash enzyme goblet cells of the bronchial mucosa. Carbocysteine ​​normalizes the quantitative ratio of acidic and neutral sialomucins of bronchial secretion, restores its viscosity and elasticity. Activates the activity of the ciliated epithelium and improves mucociliary clearance. Promotes regeneration of the mucous membrane of the respiratory tract, normalizes its structure, reduces the hyperplasia of goblet cells and, as a consequence, reduces the production of mucus. Restores the secretion of immunologically active IgA (specific protection) and the number of sulfhydryl groups of mucus components (non-specific protection). It has an anti-inflammatory effect due to the kinin-inhibiting activity of sialomucins, which reduces edema and bronchoobstruction.

Pharmacokinetics

After oral administration, the drug is rapidly absorbed in the gastrointestinal tract. The maximum concentration in blood plasma is reached in 2 hours. The bioavailability of carbocysteine ​​is low (about 10% of the dose) due to intensive metabolism in the gastrointestinal tract and due to the effect of the first passage through the liver. The half-life is about 2 hours. Carbocysteine ​​and its metabolites are excreted mainly in the urine.

INDICATION
Treatment of symptoms of disorders of bronchial secretion and sputum excretion, especially in acute bronchopulmonary diseases, such as acute bronchitis in exacerbations of chronic diseases of the respiratory system.

CONTRAINDICATION
Hypersensitivity to carbocysteine ​​or to any components of the drug (especially to methyl parahydroxybenzoate or other salts of parahydroxybenzoate), peptic ulcer of the stomach and duodenum in the acute phase.